Core Viewpoint - Zai Ding Pharma (ZLAB) has shown a positive market performance with a 2.1% increase in stock price, reaching $34.205 per share, and a total market capitalization of $3.823 billion as of August 21 [1] Financial Performance - As of June 30, 2025, Zai Ding Pharma reported total revenue of $216 million, reflecting a year-on-year growth of 15.35% [1] - The company recorded a net loss attributable to shareholders of $89.165 million, which represents a year-on-year increase of 33.33% [1] Company Overview - Zai Ding Pharma is a patient-centric, innovative global biopharmaceutical company that is in the commercialization stage, focusing on providing optimal and first-in-class drugs for oncology, autoimmune diseases, infectious diseases, and central nervous system disorders [1] - The company's mission is to become a leading global biopharmaceutical company, delivering transformative innovative drugs to patients in China and worldwide [1] - Zai Ding Pharma aims to establish itself as a global leader in biopharmaceuticals, leveraging its base in China to provide innovative therapies for patients globally [1]

8月13日，再鼎医药(ZLAB)开盘上涨2.3%，截至21:30，报35.1美元/股，成交6.09万美元，总市值39.23 亿美元。 8月7日，再鼎医药2025财年中报归属股东应占溢利-8917万美元，同比增长33.33%，基本每股收益-0.08 美元。 财务数据显示，截至2025年06月30日，再鼎医药收入总额2.16亿美元，同比增长15.35%；归母净利 润-8916.5万美元，同比增长33.33%。 大事提醒： 本文源自：金融界 作者：行情君 资料显示，再鼎医药有限公司是一家以患者为中心的、处于商业化阶段的创新型全球生物制药公司,立 足中国、全球运营,致力于为中国及全球的患者提供针对肿瘤、自身免疫性疾病、感染性疾病和中枢神 经系统疾病的同类最优和同类首创药物。公司的使命是成为全球领先的生物制药公司,为中国和世界各 地的患者提供变革性创新药物。再鼎医药的长期目标是成为全球领先的生物制药公司,以中国为基,为全 球患者提供创新疗法。 ...

Group 1 - The stock price of Zai Lab (ZLAB) opened at $34.85 per share, up 2.26%, with a total market capitalization of $3.832 billion as of August 8 [1] - For the fiscal year ending March 31, 2025, Zai Lab reported total revenue of $106 million, representing a year-over-year growth of 22.19%, while the net profit attributable to shareholders was -$48.438 million, showing a year-over-year increase of 9.41% [1] Group 2 - Zai Lab is a patient-centered, innovative global biopharmaceutical company that is in the commercialization stage, focusing on providing optimal and first-in-class drugs for oncology, autoimmune diseases, infectious diseases, and central nervous system disorders [2] - The company's mission is to become a leading global biopharmaceutical company, offering transformative innovative drugs to patients in China and around the world [2] - Zai Lab's long-term goal is to establish itself as a global leader in biopharmaceuticals, leveraging its base in China to provide innovative therapies for patients worldwide [2]